COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,637 Articles (22,913 medRxiv, 8,724 bioRxiv)

Most recent first Previous |  Page 130: Articles 1291-1300  | Next

Immune-Coagulation Dynamics in Severe COVID-19: Insights from Autoantibody Profiling and Transcriptomics
Ambikan, A., Cederholm, A., Rezene, S., Guillen, M. A., Nordqvist, H., Treutiger, C. J., Lira-Junior, R., Landegren, N., Gupta, S.
10.1101/2025.03.14.643398 — Posted: 2025-03-17
The impact of the COVID-19 pandemic on secondary prevention of Rheumatic Heart Disease in Western Uganda
Xu, X., Chu, E., Atala, J., Kansiime, R., Nakitto, M., Ndagire, E., Nalubwama, H., Okello, E., Pulle, J., Watkins, D. A., Longenecker, C., Coronado, G., Su, Y.
10.1101/2025.03.14.25323941 — Posted: 2025-03-15
Mental health in the short- and long-term adaptation processes of university students during the COVID-19 pandemic: A systematic review and meta-analysis
Jimenez Villamizar, M. P., Comendador Vazquez, L., Sanabria-Mazo, J. P., Mateo-Canedo, C., Losilla, J.-M., Muro, A., Sanz, A.
10.1101/2025.03.14.25323978 — Posted: 2025-03-15
Cleaved vs. Uncleaved: How Furin Cleavage Reshapes the Conformational Landscape of SARS-CoV-2 Spike
Mani, N., Suresh, R., Chakraborty, S.
10.1101/2025.03.12.642945 — Posted: 2025-03-14
The use of angiotensin-converting enzyme inhibitors but not angiotensin receptor blockers in hospitalized patients with COVID-19 is associated with a lower risk of mortality
Khalangot, M., Gurianov, V., Zakharchenko, T., Kravchenko, V., Kovzun, O., Shupachynskiy, V., Tronko, M.
10.1101/2025.03.12.25323615 — Posted: 2025-03-14
Predictors of first-dose COVID-19 vaccine uptake in Benin: Evidence from a cross-sectional study based on a telephonic survey
AVAHOUNDJE, E. M., BOYI HOUNSOU, C., BELLO, K., VIGAN, A. A., AGOSSOU, M. C., AGBODJAVOU, M. K., GAYE, I., BA, M. F., FAYE, A., RIDDE, V., DOSSOU, J.-P.
10.1101/2025.03.12.25323828 — Posted: 2025-03-14
Strain-specific anti-RBD IgG antibody titers against the WT, XBB.1.5, JN.1, and KP.3 strains consistently correlate with neutralizing activity following SARS-CoV-2 XBB.1.5-adapted mRNA vaccination.
Goto, T., Chong, Y., Sato, T., Tani, N., Saiki, S., Ishida, S., Kawai, N., Bando, T., Ikematsu, H.
10.1101/2025.03.13.25323892 — Posted: 2025-03-14
Intranasal AAV Vaccination of SARS-CoV-2 Induce Strong and Sustained Neutralizing Antibodies in Mice
Ji, Y., Di Pasquale, G., Zheng, C., Afione, S., Esperanza, T., Yin, H., Burbelo, P. D., Chiorini, J. A.
10.1101/2025.03.14.640671 — Posted: 2025-03-14
Implementation of a multiplex PCR amplfication system combined with next-generation genome sequencing to decipher the circulation of Human coronavirus 229E lineages in Southern France
HIKMAT, H., PY, J., BOSCHI, C., BUREL, E., LE TARGA, L., MILLION, M., LESAGE, L., MORAND, A., LA SCOLA, B., COLSON, P.
10.1101/2025.03.12.639729 — Posted: 2025-03-14
Community Perspectives on COVID-19 Vaccine Allocation Ethical Principles in Uganda: A Descriptive Cross-Sectional Study
Kiguli, J., Ssebibubbu, S., Nabaliisa, J., Nalwadda, C., Kirunda, B. R., Kamweri, M.
10.1101/2025.03.12.25323855 — Posted: 2025-03-13

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).